UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae S-C, Isenberg D, Rahman A, Hansen JE, St Pierre Y, Clarke AE
  • Publisher:
    Journal of Rheumatology
  • Publication date:
    15/01/2018
  • Journal:
    The Journal of rheumatology
  • Medium:
    Print-Electronic
  • Status:
    Published
  • Print ISSN:
    0315-162X
  • Language:
    eng
  • Addresses:
    From The Research Institute of the McGill University Health Centre, Montreal; Université de Laval, Service de rheumatologie, Quebec City, Quebec; Toronto Western Hospital, Toronto, Ontario; Dalhousie University and Capital Health, Halifax, Nova Scotia; University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada; Northwestern University Feinberg School of Medicine, Chicago, Illinois; Johns Hopkins University School of Medicine, Baltimore, Maryland; University of California at San Francisco, Department of Medicine, San Francisco, California; State University of New York-Downstate Medical Center, Brooklyn; The Feinstein Institute for Medical Research, Manhasset, New York; Therapeutic Radiology, Yale University, New Haven, Connecticut, USA; University of Birmingham, College of Medical and Dental Sciences, Birmingham; University College London, Faculty of Medicine, Department of Rheumatology, London, UK; Lund University Hospital, Lund, Sweden; The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea. Supported by the US National Institutes of Health (NIH; grant #43727) and the Canadian Institutes of Health Research. The Johns Hopkins systemic lupus erythematosus (SLE) cohort research activities are funded by the NIH AR grant #43727. The Montreal SLE cohort research activities are funded by the Singer Family Fund for Lupus Research. Dr. Bernatsky is the recipient of a senior career award from Fonds de recherche du Québec-Sante. Dr. Fortin is the recipient of a Canada Research Chair. The Northwestern SLE cohort is supported by NIH AR grant #066464. The Birmingham UK lupus cohort has been supported by Lupus UK and the Birmingham National Institute for Health Research/Wellcome Trust Clinical Research Facility. The Korea lupus cohort was supported in part by an unrestricted grant to Hanyang University: 201600000001387. S. Bernatsky, MD, PhD, The Research Institute of the McGill University Health Centre; R. Ramsey-Goldman, MD, MPH, Northwestern University Feinberg School of Medicine; M. Petri, MD, MPH, Johns Hopkins University School of Medicine; M.B. Urowitz, MD, Toronto Western Hospital; D.D. Gladman, MD, Toronto Western Hospital; P.R. Fortin, MD, MPH, Université de Laval, Service de rheumatologie; E.H. Yelin, PhD, MCP, University of California, Department of Medicine; E. Ginzler, MD, MPH, State University of New York-Downstate Medical Center; J.G. Hanly, MD, Dalhousie University and Capital Health; C. Peschken, MD, MSc, University of Manitoba; C. Gordon, MD, University of Birmingham, College of Medical and Dental Sciences; O. Nived, MD, PhD, Lund University Hospital; C. Aranow, MD, The Feinstein Institute for Medical Research; S.C. Bae, MD, PhD, MPH, The Hospital for Rheumatic Diseases, Hanyang University; D. Isenberg, MD, University College, Faculty of Medicine, Department of Rheumatology; A. Rahman, MB, ChB, PhD, University College, Faculty of Medicine, Department of Rheumatology; J.E. Hansen, MD, MS, Therapeutic Radiology, Yale University; Y. St. Pierre, MSc, The Research Institute of the McGill University Health Centre; A.E. Clarke, MD, MSc, Division of Rheumatology, Cumming School of Medicine. Address correspondence to Dr. S. Bernatsky, The Research Institute of the McGill University Health Centre, 5252 Boulevard de Maisonneuve Ouest, 3F.51, Montreal, Quebec H4A 3S5, Canada. E-mail: sasha.bernatsky@mcgill.ca. Accepted for publication October 26, 2017.
Abstract
To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031.Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors.We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by